Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-T2C in Relapsed or Refractory CD4+ T Lymphocyte Tumors
NCT04973527Phase 1Terminated
- Sponsor
- Beijing Boren Hospital
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of LB1901 in T-cell lymphoma and T-cell leukemia, sponsored by Beijing Boren Hospital. Started Jul 2021; status: terminated.
02
Drugs
LB1901
03
Conditions
T-cell lymphomaT-cell leukemia
Beyond the preview
Go deeper on NCT04973527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973527.